– Rolling submission for suzetrigine moderate-to-severe acute pain NDA granted by FDA; first module submitted and on track to complete filing this quarter – – Successful completion of end-of-phase 2 FDA meeting for pain associated with diabetic peripheral neuropathy (DPN); Phase 3 program to
- First-of-its-kind contract with the Danish pharmaceutical and procurement organization, Amgros, is effective from today - - Vertex also announces reimbursement in Austria for ORKAMBI ® (lumacaftor/ivacaftor) to treat patients ages 6 through 11 with two copies of the F508del mutation - LONDON
- FDA grants Priority Review of the application and sets action date of February 28, 2018 - -Applications supported by positive results from two global Phase 3 studies in people with CF ages 12 and older who have two copies of the F508del mutation or one F508del mutation and one residual function
-Before patients can get access through public reimbursement, each participating province or territory must decide to reimburse KALYDECO through its individual drug program- -Approximately 100 people ages 6 and older in Canada have the G551D mutation - BOSTON --(BUSINESS WIRE)-- Vertex
- Company plans to start Phase 2b study in Q3 2012 to evaluate this interferon-free combination regimen in a total treatment duration as short as 12 weeks - - Vertex also announces the advancement of its broad portfolio of direct acting antivirals, including its two structurally-distinct nucleotide
Dedicates $50M to science, technology, engineering, arts and math (STEAM) education for underserved students and establishes The Vertex Foundation Expands global efforts for providing patient and caregiver support including access to our medicines; developing young scientists and physicians; and
– Vertex grant to JDRF supports efforts to improve clinical trial diversity in type 1 diabetes – – The Vertex Foundation grant supports the Mass General Comprehensive Sickle Cell Disease Treatment Center – – Additional Vertex Foundation grant to Year Up to support health care workforce training –
Verve to Receive $25 Million Upfront Payment and $35 Million Equity Investment, as Well as Potential Milestones and Royalties BOSTON and CAMBRIDGE, Mass., July 20, 2022 (GLOBE NEWSWIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Verve Therapeutics, Inc.
Vertex obtains an exclusive license to TreeFrog's C-Stem TM manufacturing technology in type 1 diabetes TreeFrog and Vertex to collaborate on scale-up of fully differentiated, insulin-producing pancreatic islet cells BOSTON and BORDEAUX, France , April 23, 2024 /PRNewswire/ -- Vertex
- Vertex Foundation Announces $1.5 Million Gift to Boston University’s New Center for Antiracist Research - -Biotechnology-focused curriculum established in partnership with Year Up- -Additional commitments made to STEAM education- BOSTON --(BUSINESS WIRE)--Jun.